heparin/脳卒中

BACKGROUND The risk of intracerebral hemorrhage in systemic thrombolysis for acute ischemic stroke after acetylsalicylic acid (ASA) pretreatment or with subsequent heparin is controversially discussed. METHODS 300 consecutive stroke patients were treated with recombinant tissue-type plasminogen

OBJECTIVE Current American Stroke Association/American Heart Association recommendations on the management of acute ischemic stroke do not recommend the early use of heparin because of an increased risk of bleeding complications. However, for select patients, such as those with strokes associated

Heparin has long been a contested therapy in acute ischemic stroke (AIS). In current practice, heparin is considered on a case-by-case basis, but there is no consensus as to the appropriate timing of anticoagulation or for which ischemic stroke subtypes heparin may be beneficial. To provide better

BACKGROUND Low molecular weight heparins and heparinoids may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. OBJECTIVE The objective of this review was to compare the effects of low molecular weight heparins or heparinoids

BACKGROUND Low molecular weight heparins and heparinoids may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. OBJECTIVE The objective of this review was to compare the effects of low molecular weight heparins or heparinoids

The numerous large-scale randomized clinical trials performed during the last decade on either unfractionated heparin, or low molecular weight heparin have not been able to demonstrate undisputed benefits in patients with acute ischemic stroke, compared with no treatment or aspirin. However, a large

BACKGROUND A lot of clinicians use heparin in patients with posterior circulation stroke. Frequency and risk factors of symptomatic intracerebral hematoma (ICH) in posterior circulation infarct patients anticoagulated with unfractionated heparin are not known. METHODS To determine the incidence and

Immune-mediated heparin-induced thrombocytopenia (HIT) is a rare but serious side effect of heparin therapy which presents various thromboembolic events associated with high mortality and morbidity. There have been few reports about the prevalence of HIT in acute ischemic stroke, which our

In absence of careful controlled trials, heparin therapy of ischemic stroke is based today on the clinical experience and personal belief of the physicians. Moreover, the incomplete knowledge of physiopathogenesis of ischemic stroke adds further confusion on those nosographic conditions treatable

Acute stroke treatment using aspirin and/or heparin was studied in the International Stroke Trial (IST) and Chinese Acute Stroke Trial (CAST) which randomised over 40,000 patients altogether. Combining the results demonstrated that aspirin (150-300 mg) given within 48 h of the onset of stroke

BACKGROUND Anticoagulation therapy, particularly subcutaneous heparin therapy, is recommended for cancer-associated thrombosis. However, not starting or discontinuing anticoagulation was not rare. The aim of the present study was to examine the practical issues related to anticoagulation therapy and

The evidence gathered in clinical trials of low molecular weight heparins (LMWHs) or with unfractionated heparin (UH) given subcutaneously at low or medium doses to patients with acute stroke cannot be extrapolated to the insufficiently tested effects of intravenous, weight-adjusted UH. Recent small

Several case-control studies have reported enhanced platelet activity, hypercoagulation and/or reduced fibrinolytic activity in patients with acute ischemic stroke. However, results of these studies are conflicting and do not allow to make recommendations regarding heparin treatment. The aim of